International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): Content and implementation in daily routine practice

European Journal of Pharmacology

Volumn 722, Issue 1, 2014, Pages 197-202

  Jordan, Karin ^a   Gralla, Richard ^b   Jahn, Franziska ^a   Molassiotis, Alex ^c  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

Author keywords

5 HT3 serotonin receptor antagonists; Antiemetic therapy; ASCO antiemetic guidelines; MASCC ESMO antiemetic guidelines; NCCN practice antiemesis guidelines; Neurokinin1 receptor antagonist

Indexed keywords

ANTHRACYCLINE; ANTIEMETIC AGENT; ANTIINFECTIVE AGENT; APREPITANT; BENZODIAZEPINE DERIVATIVE; CARMUSTINE; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; DEXAMETHASONE; DOLASETRON MESILATE; DOPAMINE RECEPTOR BLOCKING AGENT; FOSAPREPITANT; GRANISETRON; LOMUSTINE; METOCLOPRAMIDE; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROLEPTIC AGENT; OLANZAPINE; ONDANSETRON; PALONOSETRON; PENTOSTATIN; RAMOSETRON; SEROTONIN 3 ANTAGONIST; STEROID; STREPTOZOCIN; TROPISETRON; UNINDEXED DRUG;

CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL PRACTICE; DISEASE CLASSIFICATION; DRUG EFFICACY; HEALTH CARE QUALITY; HUMAN; MEDICAL SOCIETY; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK FACTOR;

5-HT(3) SEROTONIN RECEPTOR ANTAGONISTS; ANTIEMETIC THERAPY; ASCO ANTIEMETIC GUIDELINES; MASCC/ESMO ANTIEMETIC GUIDELINES; NCCN PRACTICE ANTIEMESIS GUIDELINES; NEUROKININ(1) RECEPTOR ANTAGONIST;

ANTIEMETICS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; INTERNATIONALITY; NAUSEA; PRACTICE GUIDELINES AS TOPIC; VOMITING;

EID: 84892883297     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.09.073     Document Type: Review

References (58)

1. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC) Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference Ann. Oncol. 9 1998 811 819
2. M. Aapro, A. Molassiotis, M. Dicato, I. Pelaez, A. Rodriguez-Lescure, D. Pastorelli, L. Ma, T. Burke, A. Gu, P. Gascon, and F. Roila The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER) Ann. Oncol. 23 2012 1986 1992
3. M.S. Aapro, A. Molassiotis, and I. Olver Anticipatory nausea and vomiting Supportive Care Cancer 13 2005 117 121
4. M.S. Aapro, and C.M. Walko Aprepitant: drug-drug interactions in perspective Ann. Oncol. 21 2010 2316 2323
5. E. Basch, A.A. Prestrud, P.J. Hesketh, M.G. Kris, P.C. Feyer, M.R. Somerfield, M. Chesney, R.A. Clark-Snow, A.M. Flaherty, B. Freundlich, G. Morrow, K.V. Rao, R.N. Schwartz, and G.H. Lyman Antiemetics: American Society of Clinical Oncology clinical practice guideline update J. Clin. Oncol. 29 2011 4189 4198
6. F.P. Bymaster, D.O. Calligaro, J.F. Falcone, R.D. Marsh, N.A. Moore, N.C. Tye, P. Seeman, and D.T. Wong Radioreceptor binding profile of the atypical antipsychotic olanzapine Neuropsychopharmacology 14 1996 87 96
7. F.P. Bymaster, D.L. Nelson, N.W. DeLapp, J.F. Falcone, K. Eckols, L.L. Truex, M.M. Foreman, V.L. Lucaites, and D.O. Calligaro Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro Schizophr. Res. 37 1999 107 122
8. T.M. Dando, and C.M. Perry Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting Drugs 64 2004 777 794
9. M. de Jonge, A. Huitema, M. Holtkamp, S. van Dam, J. Beijnen, and S. Rodenhuis Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism Cancer Chemother. Pharmacol. 56 2005 370 378
10. G. Dranitsaris, P. Leung, and D. Warr Implementing evidence based antiemetic guidelines in the oncology setting: results of a 4-month prospective intervention study Supportive Care Cancer 9 2001 611 618
11. P. Eisenberg, J. Figueroa-Vadillo, R. Zamora, V. Charu, J. Hajdenberg, A. Cartmell, A. Macciocchi, and S. Grunberg Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron Cancer 98 2003 2473 2482
12. D.S. Ettinger, D. Dwight, and M.G. Kris National comprehensive cancer network: antiemesis Clinical Practice Guidelines in Oncology 1st ed. 2005 NCCN Jenkintown
13. D.S. Ettinger, D. Dwight, and M.G. Kris National comprehensive cancer network: antiemesis Clinical Practice Guidelines in Oncology 1st ed. 2013 NCCN Jenkintown
14. P. Feyer, and K. Jordan Update and new trends in antiemetic therapy: the continuing need for novel therapies Ann. Oncol. 22 2011 30 38
15. R. Gralla, M. Lichinitser, S. Van Der Vegt, H. Sleeboom, J. Mezger, C. Peschel, G. Tonini, R. Labianca, A. Macciocchi, and M. Aapro Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron Ann. Oncol. 14 2003 1570 1577
16. R.J. Gralla An outline of anti-emetic treatment Eur. J. Cancer Clin. Oncol. 25 Suppl. 1 1989 S7 S11 (discussion S13-14)
17. R.J. Gralla, and R.A. Clark Progress in controlling emesis with cancer chemotherapy Supportive Care Cancer 1 1993 178 181
18. R.J. Gralla, L.M. Itri, S.E. Pisko, A.E. Squillante, D.P. Kelsen, D.W. Braun Jr., L.A. Bordin, T.J. Braun, and C.W. Young Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting N. Engl. J. Med 305 1981 905 909
19. R.J. Gralla, D. Osoba, M.G. Kris, P. Kirkbride, P.J. Hesketh, L.W. Chinnery, R. Clark-Snow, D.P. Gill, S. Groshen, S. Grunberg, J.M. Koeller, G.R. Morrow, E.A. Perez, J.H. Silber, and D.G. Pfister Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology J. Clin. Oncol. 17 1999 2971 2994
20. S.M. Grunberg Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis Ann. Oncol. 18 2007 223-40
21. S.M. Grunberg Obstacles to the implementation of antiemetic guidelines J. Natl. Compr. Cancer Network 7 2009 601 605
22. S.M. Grunberg, D. Osoba, P.J. Hesketh, R.J. Gralla, S. Borjeson, B.L. Rapoport, A. du Bois, and M. Tonato Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity - an update Supportive Care Cancer 13 2005 80 84
23. S.M. Grunberg, D. Warr, R.J. Gralla, B.L. Rapoport, P.J. Hesketh, K. Jordan, and B.T. Espersen Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity - state of the art Supportive Care Cancer 19 Suppl. 1 2011 S43 S47
24. J. Herrstedt Nausea and emesis: still an unsolved problem in cancer patients? Supportive Care Cancer 10 2002 85 87
25. P. Hesketh, S. Grunberg, R. Gralla, D. Warr, F. Roila, R. de Wit, S. Chawla, A. Carides, J. Lanus, M. Elmer, J. Evans, K. Beck, S. Reines, K. Horgan, and A.P.S. Group The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group J. Clin. Oncol. 21 2003 4112 4119
26. P.J. Hesketh, S.M. Grunberg, R.J. Gralla, D.G. Warr, F. Roila, R. de Wit, S.P. Chawla, A.D. Carides, J. Ianus, M.E. Elmer, J.K. Evans, K. Beck, S. Reines, and K.J. Horgan The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group J. Clin. Oncol. 21 2003 4112 4119
27. P.J. Hesketh Chemotherapy-induced nausea and vomiting N. Engl. J. Med. 358 2008 2482 2494
28. P.J. Hesketh, M.G. Kris, S.M. Grunberg, T. Beck, J.D. Hainsworth, G. Harker, M.S. Aapro, D. Gandara, and C.M. Lindley Proposal for classifying the acute emetogenicity of cancer chemotherapy J. Clin. Oncol. 15 1997 103 109
29. Italian Group for Antiemetic Research Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis J. Clin. Oncol. 16 1998 2937 2942
30. Italian Group for Antiemetic Research Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide J. Clin. Oncol. 22 2004 725 729
31. K. Jordan, A. Hinke, A. Grothey, W. Voigt, D. Arnold, H.H. Wolf, and H.J. Schmoll A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis Supportive Care Cancer 15 2007 1023 1033
32. K. Jordan, H.J. Schmoll, and M.S. Aapro Comparative activity of antiemetic drugs Crit. Rev. Oncol. Hematol. 61 2007 162 175
33. R. Kaiser Antiemetic guidelines: are they being used? Lancet Oncol. 6 2005 622 625
34. M.G. Kris, P.J. Hesketh, J. Herrstedt, C. Rittenberg, L.H. Einhorn, S. Grunberg, J. Koeller, I. Olver, S. Borjeson, and E. Ballatori Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy Supportive Care Cancer 13 2005 85 96
35. M.G. Kris, P.J. Hesketh, M.R. Somerfield, P. Feyer, R. Clark-Snow, J.M. Koeller, G.R. Morrow, L.W. Chinnery, M.J. Chesney, R.J. Gralla, and S.M. Grunberg American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006 J. Clin. Oncol. 24 2006 2932 2947
36. L. Lohr Chemotherapy-induced nausea and vomiting Cancer J. 14 2008 85 93
37. A.M. Massaro, and K.L. Lenz Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting Ann. Pharmacother. 39 2005 77 85
38. J.B. McCrea, A.K. Majumdar, M.R. Goldberg, M. Iwamoto, C. Gargano, D.L. Panebianco, M. Hesney, C.R. Lines, K.J. Petty, P.J. Deutsch, M.G. Murphy, K.M. Gottesdiener, D.R. Goldwater, and R.A. Blum Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone Clin. Pharmacol. Ther. 74 2003 17 24
39. W.C. Mertens, D.J. Higby, D. Brown, R. Parisi, J. Fitzgerald, E.M. Benjamin, and P.K. Lindenauer Improving the care of patients with regard to chemotherapy-induced nausea and emesis: the effect of feedback to clinicians on adherence to antiemetic prescribing guidelines J. Clin. Oncol. 21 2003 1373 1378
40. A. Molassiotis, M.P. Saunders, J. Valle, G. Wilson, P. Lorigan, A. Wardley, E. Levine, R. Cowan, J. Loncaster, and C. Rittenberg A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre Supportive Care Cancer 16 2008 201 208
41. R.M. Navari, C.K. Nagy, and S.E. Gray The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy Support Care Cancer 21 2013 1655-63
42. National Comprehensive Cancer Network (NCCN) National comprehensive cancer network: antiemesis Clinical Practice Guidelines in Oncology vol. 1 2007 v.1
43. M.J. Nolte, R. Berkery, B. Pizzo, L. Baltzer, D. Grossano, C.D. Lucarelli, and M.G. Kris Assuring the optimal use of serotonin antagonist antiemetics: the process for development and implementation of institutional antiemetic guidelines at Memorial Sloan-Kettering Cancer Center J. Clin. Oncol. 16 1998 771 778
44. P. Nygren, K. Hande, K.J. Petty, M. Fedgchin, K. van Dyck, A. Majumdar, D. Panebianco, M. de Smet, T. Ahmed, M.G. Murphy, K.M. Gottesdiener, V. Cocquyt, and S. van Belle Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients Cancer Chemother. Pharmacol. 55 2005 609 616
45. S. Poli-Bigelli, J. Rodrigues-Pereira, A.D. Carides, M.a.,G. Julie, K. Eldridge, A. Hipple, J.K. Evans, K.J. Horgan, and F. Lawson Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America Cancer 97 2003 3090 3098
46. B. Rapoport, K. Jordan, J. Boice, A. Taylor, C. Brown, J. Hardwick, A. Carides, T. Webb, and H.J. Schmoll Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study Supportive Care Cancer 2009 (Epub ahead)
47. F. Roila Transferring scientific evidence to oncological practice: a trial on the impact of three different implementation strategies on antiemetic prescriptions Supportive Care Cancer 12 2004 446 453
48. F. Roila, D. Donati, S. Tamberi, and G. Margutti Delayed emesis: incidence, pattern, prognostic factors and optimal treatment Supportive Care Cancer 10 2002 88 95
49. F. Roila, J. Herrstedt, M. Aapro, R.J. Gralla, L.H. Einhorn, E. Ballatori, E. Bria, R.A. Clark-Snow, B.T. Espersen, P. Feyer, S.M. Grunberg, P.J. Hesketh, K. Jordan, M.G. Kris, E. Maranzano, A. Molassiotis, G. Morrow, I. Olver, B.L. Rapoport, C. Rittenberg, M. Saito, M. Tonato, and D. Warr Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference Ann. Oncol. 21 Suppl. 5 2010 v232 v243
50. F. Roila, P.J. Hesketh, and J. Herrstedt Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference Ann. Oncol. 17 2006 20 28
51. F. Roila, M. Tonato, F. Cognetti, E. Cortesi, G. Favalli, M. Marangolo, D. Amadori, M.A. Bella, V. Gramazio, and D. Donati et al. Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone J. Clin. Oncol. 9 1991 675 678
52. M. Saito, K. Aogi, I. Sekine, H. Yoshizawa, Y. Yanagita, H. Sakai, K. Inoue, C. Kitagawa, T. Ogura, and S. Mitsuhashi Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial Lancet Oncol. 10 2009 115 124
53. J.M. Salsman, S.M. Grunberg, J.L. Beaumont, M. Rogers, D. Paul, M.L. Clayman, and D. Cella Communicating about chemotherapy-induced nausea and vomiting: a comparison of patient and provider perspectives J. Natl. Compr. Cancer Network 10 2012 149 157
54. H.J. Schmoll, M.S. Aapro, S. Poli-Bigelli, H.K. Kim, K. Park, K. Jordan, J. von Pawel, H. Giezek, T. Ahmed, and C.Y. Chan Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment Ann. Oncol. 17 2006 1000 1006
55. C.R. Shadle, Y. Lee, A.K. Majumdar, K.J. Petty, C. Gargano, T.E. Bradstreet, J.K. Evans, and R.A. Blum Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity J. Clin. Pharmacol. 44 2004 215 223
56. S. Van Belle, M.R. Lichinitser, R.M. Navari, A.M. Garin, M.L. Decramer, A. Riviere, M. Thant, E. Brestan, B. Bui, K. Eldridge, M. De Smet, N. Michiels, R.R. Reinhardt, A.D. Carides, J.K. Evans, and B.J. Gertz Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869 Cancer 94 2002 3032 3041
57. D. Warr, S.M. Grunberg, R.J. Gralla, P.J. Hesketh, F. Roila, R. Wit, A.D. Carides, A. Taylor, J.K. Evans, and K.J. Horgan The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: pooled data from 2 randomised, double-blind, placebo controlled trials Eur. J. Cancer 41 2005 1278 1285
58. W. Zhang, and F.P. Bymaster The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors Psychopharmacology 141 1999 267 278